Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105
Jefferies analyst Anthony Petrone maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $88 to $105.
A money expert who watches Tarsus Pharmaceuticals thinks the company is worth more money than they thought before—they raised their price target from $88 to $105. When experts raise their targets, it means they see good reasons to believe the company might do well, so it's worth watching what they see that we don't.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.